Search Results

You are looking at 51 - 60 of 145 items for :

  • "genetic counseling" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Kids, There’s an App for That!

germline testing in patients with cancer and wondering how in the world you might automate genetic counseling to accommodate it. This conversation got me thinking about what might already be available for patients with cancer, and I immediately thought

Full access

The Time Has Come!

Margaret Tempero

hope private insurers will follow suit. The other niggling issue here is that, without a doubt, we will find molecular abnormalities in tumors that reflect germline mutations. This obviously leads to the need for genetic counseling and germline testing

Full access

An Update on NCCN/NBGH Initiative to Develop Evidence-Based Cancer Treatment Recommendations: Year 3

Elizabeth Danielson

Benefits and Resource Guide will also address issues relevant for employees dealing with a loved one's cancer, including the impact of taking on a caregiver role, cancer risk reduction, recommended cancer screening, and understanding when genetic counseling

Full access

Understanding Cancer Risk—Genes Matter!

Margaret Tempero

testing. Accelerate education about genetic risk for primary care providers. Ramp up our support for cancer genetic counselling. Just get it done! MARGARET TEMPERO, MD Margaret Tempero, MD, is a Professor of Medicine and Director of the UCSF

Full access


they relate to individuals with a personal or family history. The extensive update includes a clarified step-by-step process for the assessment of hereditary CRC syndromes, and a greater emphasis on the importance of genetic counseling. “Many of these

Full access

NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection

Peter H. Carroll and James L. Mohler

men with high-risk, very high-risk, regional, or metastatic prostate cancer. Men with BRCA1 /2, ATM, PALB2 , or FANCA should be referred for genetic counseling and early use of platinum chemotherapy, or consider enrollment on a clinical trial. 2

Full access

Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 1.2014

Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Saundra S. Buys, Beth Crawford, Susan Friedman, Judy E. Garber, Carolyn Horton, Virginia Kaklamani, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Boris Pasche, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Georgia L. Wiesner, Mary A. Dwyer, and Rashmi Kumar

emphasized that these guidelines were not developed as a substitute for professional genetic counseling. Rather, they are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic

Full access

Advancing the Standard of Cancer Care in 2014

Robert W. Carlson

and supportive care topics. For example, this special edition includes a presentation on “Genetic Counseling in Patients with Familial Risk for Colorectal Cancer,” a topic that was translated into new NCCN Guidelines for Genetic/Familial High

Full access

Ovarian Clear Cell Carcinoma in Cowden Syndrome

Kevin Yauy, Marion Imbert-Bouteille, Virginie Bubien, Clothilde Lindet-Bourgeois, Gauthier Rathat, Helene Perrochia, Gaëtan MacGrogan, Michel Longy, Didier Bessis, Julie Tinat, Stéphanie Baert-Desurmont, Maud Blanluet, Pierre Vande Perre, Karen Baudry, Pascal Pujol, and Carole Corsini

be a promising treatment strategy for this cancer. 24 , 25 Offering family genetic testing to relatives of the proband and subsequently setting up personalized medical management is a critical component of cancer genetic counseling. Interestingly

Full access

Point: Justification for Lynch Syndrome Screening Among All Patients With Newly Diagnosed Colorectal Cancer

Heather Hampel

their relatives to undergo genetic counseling and testing to learn if they too are at increased risk for cancer and could benefit from intensive cancer surveillance. The costs of screening can be offset by the benefits of cancer prevention in the patient